Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer

NCT01767857 is registered in ClinicalTrials.gov with Janssen Research & Development, LLC as lead sponsor.

NCT NCT01767857
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01767857 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Lead sponsor
Janssen Research & Development, LLC
Phase
Phase 3
Overall status
Terminated
Start date
March 31, 2013
Completion date
June 30, 2017
Enrollment
643 (actual)
Sites
113

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer